Surrogate end-points or primary outcomes in clinical trials in women with polycystic ovary syndrome?
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
There are multiple surrogate variables in polycystic ovary syndrome (PCOS), including biometric and biochemical parameters. The number of surrogate variables and their poor validity in relationship to primary clinical end-points pose major problems to conducting a trial in women with PCOS. The aim of this review is to discuss the use of surrogate variables compared with primary clinical end-points in women with PCOS. Arguably the best documented correlation between a surrogate variable and a primary clinical end-point is that between ovulation and pregnancy in women with PCOS. Good correlation has been noted between the increase in ovulation frequency with clomiphene citrate and the chance of pregnancy in women with PCOS. However, ovulation cannot be equated with pregnancy, as a host of other factors may affect the true outcome of interest: a healthy liveborn child. Pregnancy and an improvement in hirsutism are clinical end-points that have been successfully studied in past and ongoing clinical trials in women with PCOS. Many other clinical end-points, such as endometrial cancer and cardiovascular disease, are rare in premenopausal women with PCOS, and may not be suitable as the primary outcome of clinical studies. Future multicentre trials in women with PCOS should focus on primary clinical end-points.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Amenorrhea associated with bilateral polycystic ovaries
Stein, I. F., & Leventhal, M. L. (1935) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(15)30642-6 · Cited by 2,121
Estrogen plus Progestin and the Risk of Coronary Heart Disease
Manson, J. E., Hsia, J., Johnson, K. C., Rossouw, J. E., Assaf, A. R., Lasser, N. L., Trevisan, M., Black, H. R., Heckbert, S. R., Detrano, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030808 · Cited by 2,065 · cited 1×
“Similarly, increased cardiovascular events were seen in the Women’s Health Initiative study of primary prevention of cardiovascular disease, despite favourable changes in lipid profiles with lowered levels of LDL cholesterol and elevated levels of HDL cholesterol in the treated groups (Writing Group for the Women’s He…”
BackgroundSurrogate endpoints in clinical trials: Definition and operational criteria
Prentice, R. L. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080407 · Cited by 2,057
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743 · cited 2×
“vulation has also been utilized for several large series describing metabolic sequelae in PCOS (Talbott et al., 1995; Legro et al., 1999; Talbott et al., 2000; Legro et al., 2001; Wild, 2002), several seminal clinical trials in PCOS (Nestler and Jakubowicz, 1996; Nestler et al.”
BackgroundSelf-citationBuchanan, T. A., Xiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Tan, S., Berkowitz, K., Hodis, H. N., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2796 · Cited by 1,339
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257 · cited 2×
“Small studies in women with PCOS have shown high conversion rates to type 2 diabetes over time ( Ehrmann et al., 1999; Norman et al., 2001).”
BackgroundMetformin in polycystic ovary syndrome: systematic review and meta-analysis
Lord, J. M., Flight, I. H. K., & Norman, R. J. (2003) · BMJ · doi:10.1136/bmj.327.7421.951 · Cited by 786 · cited 2×
“Several reviews have also suggested a similar benefit with metformin (Barbieri, 2003; Haas et al., 2003; Harborne et al., 2003), and a recent Cochrane meta-analysis showed a significant treatment benefit of metformin in inducing ovulation in women with PCOS ( Lord et al., 2003 ).”
BackgroundResultInfluentialNestler, J. E., & Jakubowicz, D. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350902 · Cited by 743
Cushman, M., Legault, C., Barrett-Connor, E., Stefanick, M. L., Kessler, C., Judd, H. L., Sakkinen, P. A., & Tracy, R. P. (1999) · Circulation · doi:10.1161/01.cir.100.7.717 · Cited by 660 · cited 1×
“thrombophilia that this combination may encourage (Cushman et al., 1999; Rosendaal et al., 2002).”
Cited by
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome
Legro, R. S., Barnhart, H. X., Schlaff, W. D., Carr, B. R., Diamond, M. P., Carson, S. A., Steinkampf, M. P., Coutifaris, C., McGovern, P. G., Cataldo, N. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063971 · Cited by 1,027
Self-citationPalomba, S., Orio, F., Falbo, A., Manguso, F., Russo, T., Cascella, T., Tolino, A., Carmina, E., Colao, A., & Zullo, F. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0110 · Cited by 279
The Harbin Consensus Conference Workshop Group, Chairs:, C., Legro, R. S., Wu, X., Scientific Committee:, Barnhart, K. T., Farquhar, C., Fauser, B. C. J. M., Mol, B., Legro, R. S., et al. (2014) · Human Reproduction · doi:10.1093/humrep/deu218 · Cited by 129
Self-citationPalomba, S., Falbo, A., Giallauria, F., Russo, T., Rocca, M., Tolino, A., Zullo, F., & Orio, F. (2010) · Human Reproduction · doi:10.1093/humrep/deq254 · Cited by 111
Palomba, S., Falbo, A., Battista, L., Russo, T., Venturella, R., Tolino, A., Orio, F., & Zullo, F. (2010) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2009.11.042 · Cited by 33
Metadata
- Authors
- Legro, R. S.
- Venue
- Human Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-06-03
- Volume
- 19
- Issue
- 8
- Pages
- 1697-1704
- ISSN
- 0268-1161 (ISSN-L)
- 1460-2350
- OpenAlex
- W2159347060
- Cited by
- 42
- References
- 25
- FWCI
- 4.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.